The Weekly Roundup: November 17-21

To stay up-to-date with the latest dermatology news, sign up to receive our eNewsletters.

Beyond Antibiotics: How Oral Denifanstat Could Reshape the Acne Pipeline

Denifanstat emerges as a groundbreaking oral therapy for acne, targeting sebum production and inflammation, promising safer, effective treatment options.

Roflumilast sNDA Accepted for Plaque Psoriasis in Patients 2 to 5 Years

A Prescription Drug User Fee Act target action date is set for June 29, 2026.

Q&A: How Clinicians Are Healing “Overdosed” Skin Damaged by Viral Trends

Discover how viral skin care trends on social media mislead users, compromising skin health, and learn evidence-based strategies for effective care from Nerissa Prieto, MD.

Immune Signatures Outperform Clinical Appearance in Treatment Guidance

Kilian Eyerich, MD, PhD, argues that classifying skin diseases by immune response patterns offers clearer therapeutic guidance than traditional morphology.

AEON's ABP-450 Achieves Critical Analytical Milestone, Demonstrating High Biosimilarity to BOTOX

AEON Biopharma showcases promising biosimilar data for ABP-450, indicating strong similarity to BOTOX, paving the way for FDA approval.

Skin Aging and Cellular Senescence

Explore how skin aging and cellular senescence impact overall health, revealing insights into anti-aging strategies and cosmetic conundrums.

Brian Kim, MD, MTR, FAAD, Highlights Rapid Rise of Bioelectronic Medicine

Neuroimmune modulation, including vagus nerve stimulation, is highlighted as a promising strategy for patients unresponsive to biologics.

New Survey Reveals Rise in GLP-1 Patients Seeking Cosmetic Care

GLP-1 medications are reshaping dermatology, driving increased patient demand for treatments addressing facial volume loss and jowling concerns, according to Joely Kaufman, MD.

The Hair Report: Expert Perspectives on Hair Disorders in Skin of Color

Experts discuss hair loss challenges and treatments for skin of color, highlighting the importance of early intervention and accurate diagnosis.

Lewitt Shares Strategies for Treating Vitiligo in Difficult Areas

Using multiple treatment modalities often achieves superior repigmentation compared with monotherapy.

Veradermics Launches Phase 2/3 Trial for VDPHL01, a Potential First FDA-Approved Oral Treatment for FPHL

Veradermics initiates a groundbreaking trial for VDPHL01, an oral minoxidil treatment, addressing female pattern hair loss with innovative solutions.

Training, Transparency, and Teledermatology: New Survey Uncovers Key Priorities in Patient Care

A recent survey reveals patients prioritize board-certified dermatologists and increasingly favor teledermatology for faster, accessible care.

Journal Digest: November 19, 2025

This review of the latest dermatologic studies highlights new research on acne, including post-treatment recurrence, the use of AI, severity in cystic fibrosis patients, and more.

Ungar Explores Breakthroughs in Seborrheic Dermatitis and More

Benjamin Ungar, MD, shares groundbreaking insights on seborrheic dermatitis and emerging treatments in dermatology at ISDS 2025.

DecisionDx-Melanoma GEP Test Accurately Predicts SLN Positivity and Refines Recurrence Risk Assessment, New Data Shows

New findings showcase DecisionDx-Melanoma's effectiveness in predicting sentinel lymph node positivity and enhancing recurrence risk assessment in melanoma patients.

Innovations Transforming How We Manage HS

Discover the latest insights on hidradenitis suppurativa treatment, emerging therapies, and the importance of compassionate care for patients.

The Dermatology Clinician's Role in Detecting Intimate Partner Violence

Stacey Swinehart, DNP, FNP-BC, DCNP, CNL, shares key takeaways for clinicians from the SDNP's recent webinar on detecting intimate partner violence among patients.

BOTOX Cosmetic Day 2025: Vince Bertucci, MD, FRCPC, Discusses Diversity, Psychological Benefits, and Natural Outcomes

Discover how BOTOX Cosmetic Day highlights natural results and patient satisfaction, backed by new research from ASDS on diverse populations and effective treatment strategies.

Highlighting Collaborative Practice and JAK Inhibitor Stewardship

At Elevate-Derm 2025, Diego Ruiz Dasilva, MD, emphasized cross-role teamwork and urged clinicians to consider positive JAK inhibitor safety data.

JAK3 Inhibitor Ritlecitinib Links Molecular Change to Visible Regrowth

New research reveals ritlecitinib's potential to reverse scarring alopecias by targeting inflammation, offering hope for hair regrowth in autoimmune disorders.

Cutaneous Lymphomas Offer Insights Into Chronic Skin Inflammation

Dupilumab clears AD clinically and histologically, but deep immune profiling shows disease-memory T cells persist in the skin.

Joely Kaufman, MD, on Proactively Integrating GLP-1 Use into Aesthetic Practice

Clinicians can enhance aesthetic outcomes by proactively managing GLP-1 patients' expectations, addressing facial changes early, and integrating holistic treatment strategies.

Rising Antimicrobial Resistance Demands New Strategies

At Elevate-Derm Fall, Ted Rosen, MD, detailed how rapidly evolving resistance in bacteria, fungi, viruses, and more is reshaping therapeutic choices.

Lewitt Highlights Early Treatment Benefits of Topical JAK Inhibitors

Michael Lewitt, MD, emphasizes adherence to twice-daily application as the primary determinant of clinical success.

Key Considerations and Best Practices for Aesthetic Procedures in Skin of Color

Nada Elbuluk, MD, MSc, and Nkem Ugonabo, MD, MPH, discuss safe aesthetic procedures for skin of color, emphasizing tailored techniques and the importance of understanding unique skin biology.

Bridging the Literacy Gap to Strengthen Dermatologic Care

At Elevate-Derm Fall, Ken Korber, PA-C, MHPE, DFAAPA, highlighted how literacy-aware communication and team-based collaboration can elevate patient understanding and adherence.

Exploring a Rapidly Evolving Therapeutic Landscape

Maui Derm NP+PA Fall 2025 conference showcases cutting-edge insights in dermatology, featuring expert discussions on skin cancer, atopic dermatitis, and rare dermatoses.

Guselkumab Demonstrates Durable Joint-Protective Effects Through 48 Weeks in Active PsA

New long-term findings reveal guselkumab (TREMFYA) as the only IL-23 inhibitor effectively preventing joint damage in active psoriatic arthritis.

JAKs, STATs, and New Targets in Inflammatory Skin Disease

Massimo Gadina, PhD, underscored the need for genetics-guided patient selection to improve treatment specificity in inflammatory skin diseases.

How Teledermatology and Provider Diversity Combat Systemic Barriers in Skin of Color Care

Mondana Ghias, MD, FAAD, discusses Tono Health's role in improving access to skin care for patients of color, addressing systemic barriers and enhancing diagnostic accuracy.

ISDS 2025: Full Conference Recap

Explore the latest advancements and expert insights from ISDS 2025 held in New York, New York.